Month: May 2012

A dissolving drug carrier

Dissolvable Drug Carrier

Dithio-bis(ethyl 1H-imidazole-1-carboxylate) crosslinks with protein amine groups. The dissulfide gets reduced in the cellular environment.

Researchers are always looking for ways to improve the cellular delivery of drugs. Many times they use polymers or protein particles. Protein particles offer immediate biocompatibility, but since they are water soluble they tend to break up rapidly once they enter the bloodstream.  Now researchers have applied crosslinking to allow protein particles together until they enter a cell, where they are then dissolved. From C&EN:

His team achieved this solubility switch by stitching together the proteins once they had formed a particle. They used a compound called dithio-bis(ethyl 1H-imidazole-1-carboxylate) (DIC), which crosslinks proteins via their amine groups. This crosslinking holds the proteins together and prevents the particle from dissolving. But the crosslinking compound contains a disulfide bond that breaks in reducing environments, such as inside a cell, explains DeSimone. So once the particle slips into a cell, it breaks apart, dissolves, and releases its cargo. In addition, when the disulfide bonds break, the remaining halves of the DIC molecule fall off the amine groups, restoring the proteins to their unmodified state.

To test the protein-stitching technique, the researchers first made protein particles using a method they had developed previously (J. Am. Chem. Soc., DOI: 10.1021/ja8014428). They combined bovine serum albumin, an inexpensive protein, with glycerol and α-D-lactose, which act as glues to hold the protein matrix together. As test cargo, they mixed in a large RNA molecule that codes for the enzyme chloramphenicol acetyltransferase. To form the particles, the researchers poured this mixture into a mold to solidify. They pulled the protein particles from their molds with sticky paper and then dissolved the adhesive to release the particles.

controversial flu research

Controversial flu research finally gets published. A while the Kawaoka lab at the University of Wisconsin, Madison figured out how to make a version of the H5N1 bird flu virus. The research was put on hold and a government advisory panel decided that it shouldn’t be published until they had a chance to review it due to fears of bioterrorism and pandemics. The panel authorized publication back in March and the research appears in the May 2nd edition of Nature. Another article on the topic from a different lab is expected to be published later this year in Science.  From ScienceNews:

A controversial research paper by Wisconsin researchers that details how to make an airborne version of the H5N1 avian influenza virus is finally making its public debut.

Published online May 2 in Nature, the paper, as well as a similar one by Dutch authors, spells out genetic changes that may render the bird virus infectious between humans by airborne transmission. In November, a U.S. government advisory panel decided that information about creating a fully lethal and transmissible form of the virus should not be published.

H5N1 kills more than half the people it infects, but the virus doesn’t spread from person to person. Revised versions of both research groups’ papers make it clear that airborne, contagious versions of the virus made in the lab don’t retain the killing capacity of the original avian flu. So in March the advisory panel revised its decision to allow full publication of both studies. The Dutch group’s study is still under review in the journal Science.

the psychedelic brain

Magic shrooms calm the brain. From Scientific American:

Researchers have long suspected that the altered perception, kaleidoscopic visions and mood changes produced by psych­edelic drugs reflect a jump in brain activity. Not so, say neuroscientists at Imperial College London and elsewhere. They used functional MRI to peek at the brains of 30 participants experiencing a “trip” induced by intravenously delivered psilocybin, a psychedelic found in magic mushrooms. As they reported in the Proceedings of the National Academy of Sciences USA online in January, investigators saw psilocybin-related dips in brain activity, particularly in control centers such as the thalamus, the anterior and posterior cingulate cortices, and the medial prefrontal cortex. The more placid these regions appeared in a participant’s brain, the more intense the subject’s self-reported psychedelic experiences. The scientists conclude that psychedelics temporarily flip off cognition-constraining pathways—including some that are overactive during depression. [For more on this study, click here.]

//toosegaptisaiw.net/4/4535925